Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-10-06 07:54:56 - browse：7

Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a set of provisions the industry says will warp how cancer drugs are developed. On Wednesday, AstraZeneca CEO Pascal Soriot proposed a new solution.

“What we were asking — and are asking now — is a very simple fix,” said Soriot at the STAT Future Summit, saying that “the impact on health care costs would be very marginal.”

The problem, executives say, is that companies developing cancer drugs today generally start small and then go big. They seek approval first in a small setting, such as patients who have exhausted all other therapies, where it’s easiest in terms of trial size and length to show a benefit. Then they go into larger settings, such as newly diagnosed patients, where studies take longer but the revenue potential is much higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Medical mystery: When a cough is not just a cough

WSS

Medicare threatens to cut off funding for HCA's Mission hospital

Readout LOUD podcast: How biotech is using artificial intelligence

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Why did Pfizer dish out millions for a Super Bowl ad?

Senators start work on Medicare physician payment reform

Antibiotic resistance and the global rise in human conflict

focus

Wikipedia

hotspot

At least 13 dead in Texas as scorching temps continue

Private equity deals in Medicare Advantage declines

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Ahead of JPM, here's who's profiting most in health care

In age of alternative facts, a scholarly course on calling out crap

J&J to buy cancer drug developer Ambrx Biopharma

Drug repurposing or repositioning? The language matters

Medicare threatens to cut off funding for HCA's Mission hospital

Hollywood unions extend contract negotiations for actors

The Readout: Gilead, Bernie Sanders, and other pharma news

entertainment

BioAge raises $170M for combination therapy with Zepbound

Gilead might be held responsible for not developing a drug

Medicare Advantage proposed rates disappoint insurers

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

How a scoliosis diagnosis changed the life of one young dancer

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

entertainment

focus

focus

hotspot